Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Med (Lausanne)
Autori principali: Mika, Thomas, Strate, Katharina, Ladigan, Swetlana, Aigner, Clemens, Schlegel, Uwe, Tischoff, Iris, Tischer-Zimmermann, Sabine, Eiz-Vesper, Britta, Maecker-Kolhoff, Britta, Schroers, Roland
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2019
Soggetti:
Medicine
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930172/
https://ncbi.nlm.nih.gov/pubmed/31921871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2019.00295
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi